JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

The past, present, and future of FIGO staging of endometrial cancer

  • 0Department of Gynecology, Affiliated Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University, Shenyang, China.
Journal of Gynecologic Oncology +

|

May 12, 2025

|

May 12, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

The 2023 International Federation of Gynecology and Obstetrics (FIGO) staging for endometrial cancer (EC) improves prognostic accuracy but introduces complexity. Further research is needed to address unresolved issues for personalized patient management.

Area Of Science

  • Gynecologic Oncology
  • Pathology
  • Cancer Staging

Background

  • The International Federation of Gynecology and Obstetrics (FIGO) staging system is vital for endometrial cancer (EC) treatment, prognosis, and research.
  • A new FIGO staging system for EC was released in June 2023.
  • Accurate staging is crucial for gynecologic oncologists, pathologists, and patients.

Purpose Of The Study

  • To comprehensively review the evolution of FIGO staging for EC.
  • To highlight differences between the 2023 FIGO staging and previous systems.
  • To discuss the integration of pathological factors and molecular subtypes into EC staging.

Main Methods

  • Review of the developmental trajectory of FIGO staging for EC.
  • Analysis of the 2023 FIGO staging system in comparison to earlier versions.
  • Examination of the advantages and disadvantages of incorporating pathological factors and molecular subtypes.

Main Results

  • The 2023 FIGO staging enhances prognostic prediction accuracy for EC patients.
  • Increased complexity in the updated staging system may challenge accurate application by healthcare professionals.
  • Persistent unresolved issues include histological types, grading, lymphovascular invasion, and molecular subtypes.

Conclusions

  • The 2023 FIGO staging represents progress in prognostic accuracy for endometrial cancer.
  • Complexity and unresolved issues necessitate further clinical research for validation and personalized management.
  • Addressing these challenges is a shared goal for gynecologic oncologists and pathologists.

Keywords: